Bimeda UK is pleased to announce the re-launch of Multishield Dry Cow (POM-V) to the UK market place.
The non-cephalosporin containing dry cow tube contains 100mg Neomycin Sulphate, 100mg Penethemate Hydriodide and 400mg Procaine Benzylpenicillin and is a welcome addition to Bimeda’s growing dairy production category, which includes such products as Boviseal non-antibiotic teat sealant, as well as a range of anti-inflammatories, anti-microbials and anti-parasitics, hormones and nutritional products licensed for use in dairy cattle.
Bimeda Professional Services Veterinarian, Rachel Mallet BVM&S MRCVS, commented; ‘Multishield DC treats a wide variety of mastitis-causing bacteria. With its fast and slow-release penicillin, Multishield DC offers fast-acting yet prolonged activity. The fact that it works synergistically with the other ingredients makes this a great option for UK farmers at dry-off. UK vets have been eagerly anticipating the re-introduction of Multishield, which is an excellent choice for use as part of a mastitis control programme, in conjunction with teat sealants such as Boviseal. While Boviseal acts as a physical barrier to prevent new infection, Multishield DC treats existing infections’.
Multishield DC has a meat withdrawal of 28 days and a milk withdrawal of 96 hours post-calving in cows with a dry period of more than 50 days. Each pack contains 120 syringes.
To coincide with the relaunch of Multishield DC, Bimeda is launching their guide to Selective Dry Cow Therapy. Rachel noted; ‘worldwide, the animal health industry is coming under increasing pressure to move away from a ‘blanket approach’ to antibiotic use, towards a more targeted approach. However, for some farmers this is a completely new concept and there is a significant knowledge gap in this area. We have produced the Bimeda Guide To Selective Dry Cow Therapy which is a tool for vets to use in conjunction with their clients, to help them understand when and how it is appropriate to introduce a selective dry cow therapy approach, which should only be introduced in consultation with a vet’.
Head of Sales for Bimeda UK, James Hutchings, commented, ‘the reintroduction of Multishield and the launch of our training materials and literature highlights our ongoing commitment to providing the UK veterinary sector with both high quality products at a competitive price point, as well as the support materials they need to help their farming clients introduce best-practice on-farm protocols’.
For more information on Multishield DC, or if you would like to order the free-of-charge Bimeda Guide To Selective Dry Cow Therapy, contact your Bimeda Sales Representative or call Bimeda on 01248 725 400
Multishield DC is registered POM-V medicine. Vm: 12597/4058. Full product information, including contra-indications, can be found on the SPC which is available on the VMD website. Alternatively, see Bimeda.co.uk.
Use Medicines Responsibly. www.noah.co.uk